<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The amino acids <z:chebi fb="0" ids="29988">L-glutamate</z:chebi> and <z:chebi fb="0" ids="29993">L-aspartate</z:chebi> have been shown to be excitatory <z:chebi fb="65" ids="25512">neurotransmitters</z:chebi> in mammalian central <z:mp ids='MP_0008912'>nervous</z:mp> systems </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="68" ids="48706">Antagonists</z:chebi> acting selectively at excitatory amino acid receptors have shown <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> properties in several animal models </plain></SENT>
<SENT sid="2" pm="."><plain>We report the results of the first therapeutic trial of the competitive <z:chebi fb="0" ids="31882">NMDA</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi>, D-CPP-ene (SDZ EAA-494), in eight patients with intractable <z:hpo ids='HP_0002384'>complex partial seizures</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients withdrew prematurely because of side-effects, including poor concentration (8), sedation (7), <z:hpo ids='HP_0001251'>ataxia</z:hpo> (6), <z:hpo ids='HP_0000716'>depression</z:hpo> (3), <z:hpo ids='HP_0001260'>dysarthria</z:hpo> (2), <z:e sem="disease" ids="C0002622" disease_type="Mental or Behavioral Dysfunction" abbrv="">amnesia</z:e> (2) and unilateral choreo-<z:hpo ids='HP_0002305'>athetosis</z:hpo> in a patient with contralateral <z:e sem="disease" ids="C0038505" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="PKWS">Sturge-Weber syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0001250'>Seizures</z:hpo> were unchanged in four patients and worse in three </plain></SENT>
<SENT sid="5" pm="."><plain>A further patient with apparent improvement in <z:hpo ids='HP_0001250'>seizures</z:hpo> in the first week developed complex partial <z:hpo ids='HP_0002133'>status epilepticus</z:hpo> on withdrawal of DCPP-ene </plain></SENT>
<SENT sid="6" pm="."><plain>EEG on treatment (5) or in the immediate post-treatment period (2) showed slowing of background activity and, in five cases, an increase in epileptiform activity </plain></SENT>
<SENT sid="7" pm="."><plain>Serum concentrations of DCPP-ene were found to be unpredictable and higher than expected from pharmacokinetic data on <z:mpath ids='MPATH_458'>normal</z:mpath> subjects </plain></SENT>
<SENT sid="8" pm="."><plain>There was no clear relationship between serum concentrations and the severity of side-effects </plain></SENT>
<SENT sid="9" pm="."><plain>Preliminary experience with DCPP-ene in patients with refractory <z:hpo ids='HP_0007359'>partial seizures</z:hpo> is not promising </plain></SENT>
<SENT sid="10" pm="."><plain>Evaluation of related compounds is warranted </plain></SENT>
</text></document>